Low-molecular-weight heparins in non-ST-segment elevation ischemia: The ESSENCE trial

American Journal of Cardiology

Volumn 82, Issue 5 B, 1998, Pages 19L-24L

  Cohen, Marc ^a   Demers, Christine ^b   Gurfinkel, Enrique P ^b   Turpie, Alexander G G ^b   Fromell, Gregg J ^b   Goodman, Shaun ^b   Langer, Anatoly ^b   Califf, Robert M ^b   Fox, Keith A A ^b   Premmereur, Jerome ^b   Bigonzi, Frederique ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO;

ACUTE HEART INFARCTION; ADULT; ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ECCHYMOSIS; FEMALE; HUMAN; INJECTION SITE; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0032504937     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00108-8     Document Type: Conference Paper

References (25)

1. Braunwald E, Mark DB, Jones RH, Cheitlin MD, Fuster V, McCaulay KM, Edwards C, Green LA, Mushlin AI, Swain JA, Smith EE III, Cowan M, Rose GC, Concannon CA, Grines CL, Brown L, Lytle BW, Goldman L, Topol EJ, Willerson JT, Brown J, Archibald N. Unstable angina: diagnosis and management. Clinical practice guideline number 10 AHCPR Publication-No. 94-0602: Agency for health care policy and research, US Department of Health and Human Services. May 1994.
2. Theroux P, Ouimet H, McCans J, Latour JG, Joly P. Levy G, Pelletier E, Juneau M, Stasiak J, deGuise P, Pelletier GB, Rinzler D, Waters DD. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319:1105-1111.
3. Wallentin L for the RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827-830.
4. Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I, Fox KAA, Chesebro JH, Strain J, Keller C, Kelly A, Lancaster G, Ali J, Kronmal R, Fuster V, and the Anti-thrombotic Therapy in Acute Coronary Syndromes Research Group. Combination antithrombotic therapy in rest unstable angina and non-q wave infarction in non-prior aspirin users: primary endpoints analysis from the ATACS trial. Circulation 1993;89:81-88.
5. Wallentin L for the Fragmin during instability in coronary artery disease (FRISC) Study Group. Low-molecular weight heparin during instability in coronary artery disease (FRISC) Study Group: low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-568.
6. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA 1996;276:811-815.
7. Antman EA for the TIMI 9B Investigators. Hirudin in acute myocardial infarction: thrombosis and thrombin inhibition in myocardial infarction (TIMI) 9B Trial. Circulation 1996;94:911-921.
8. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79:1-17.
9. Melandri G, Semprini F, Cervi V, Candiotti N, Branzi A, Palazzini E, Magani B. Comparison of efficacy of low molecular weight heparin (Parnaparin) with that of unfractionated heparin in the presence of activated platelets in healthy subjects. Am J Cardiol 1993;72:450-454.
10. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after discontinuation of heparin. N Engl J Med 1992;327:141-145.
11. Samama MM, Bara L, Gerotziafas GT. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs). Haemostatis 1994;24:105-117.
12. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332: 1330-1335.
13. Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes DW, Vandenbroucke JP, Briet E. Low molecular weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992;340:152-156.
14. Gurfinkel EP, Manos EJ, Mejail RI, Cerda MA, Duronto EA, Garcia CN, Doroca AM, Mautner B. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995;26:313-318.
15. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KAA, Premmereur J, Bigonzi F. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-452.
16. Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Boissell JP. Low molecular weight heparin in prevention of preoperative thrombosis. Br Med J 1992;305:913-920.
17. Prandoni P, Lensing AWA, Buller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, Ten Cate JM. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal deep vein thrombosis. Lancet 1992;339:441-445.
18. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR, Norton J, Carter CJ, Merli G, Ward J, Mayo W, Rosenbloom D, Brant R. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992;326:975-982.
19. Kakkar VV, Cohen AT, Edmonson RA, Phillips MJ, Cooper DJ, Das SK, Maher KT Sanderson RM, Ward VP, Kakkar S. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993;341:259-265.
20. Leclerc JR, Geerts WH, Desjardins L, Jobin F, Laroche F, Delorme F, Haviernick S, Atkinson S, Bourgouin J. Prevention of deep vein thrombosis after major knee surgery: a randomized, double-blind trial comparing a low molecular weight heparin fragment (Enoxaparin) to placebo. Thrombosis Haemostasis 1992;67:417-423.
21. Spiro TE, Johnson GJ, Christie MJ, Lyons RM, MacFarlane DE, Blasier RB, Tremaine MD for the Enoxaparin Clinical Trial Group. Efficacy and safety of Enoxaparin to prevent deep vein thrombosis after hip replacement surgery. Ann Intern Med 1994;121:81-89.
22. Levine M, Gent M, Hirsh, J, Leclerc J, Anserson D, Weitz J, Ginberg J, Turpie AG, Demers C, Kovacs M, Geerts W, Kassis J, Desjardins L, Cusson J, Cruickshank M, Powers P, Brien W, Haley S, Willan A. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 1996;334:677-681.
23. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, Van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH, Bossuyt PMM, De Haes H, Van den Belt AGM, Sagnard L, D'Azemar P, Buller HR. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular weight heparin administered at home. N Engl J Med 1996;334:682-687.
24. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AG, van der Meer J, Olaisson E, Undeland S, Ludwig K. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation, 1997;96:61-8.
25. Antman EM. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol 1997;29:1474-1482.